Dr Reddy's Laboratories slipped to its 52-week low of Rs 2,602, down 5% on BSE in intra-day trade on back of heavy volumes.
The BSE said the exchange has sought clarification from Dr Reddys Laboratories on March 21, 2017, with reference to news flashed on ET Now dated March 21, 2017 quoting "US FDA finds repeat observations from 2015 warning letter. Failed to maintain complete data to ensure compliance."
The reply is awaited.
Earlier, on March 9, 2017, the stock of pharmaceutical company hit a low of Rs 2,702 after it said the US drug regulator issued
The BSE said the exchange has sought clarification from Dr Reddys Laboratories on March 21, 2017, with reference to news flashed on ET Now dated March 21, 2017 quoting "US FDA finds repeat observations from 2015 warning letter. Failed to maintain complete data to ensure compliance."
The reply is awaited.
Earlier, on March 9, 2017, the stock of pharmaceutical company hit a low of Rs 2,702 after it said the US drug regulator issued